Rituximab, Bendamustine Hydrochloride, and Lenalidomide in Treating Patients With Aggressive B-Cell Lymphoma
Rituximab, Bendamustine and Lenalidomide in Patients With Aggressive B-cell Lymphoma Not Eligible for High Dose Chemotherapy or Anthracycline-Based Therapy. A Phase I/II Trial.
Sponsor: Swiss Cancer Institute
A PHASE1/PHASE2 clinical study on Lymphoma, this trial is completed. The trial is conducted by Swiss Cancer Institute and has accumulated 8 data snapshots since 2009. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE1/PHASE2
-
Aug 2025 — Sep 2025 [monthly]
Completed PHASE1/PHASE2
-
Sep 2024 — Aug 2025 [monthly]
Completed PHASE1/PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1/PHASE2
Phase: PHASE1_PHASE2 → PHASE1/PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1_PHASE2
▶ Show 3 earlier versions
-
Jun 2019 — Jan 2021 [monthly]
Completed PHASE1_PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Completed PHASE1_PHASE2
-
Jan 2017 — Jun 2018 [monthly]
Completed PHASE1_PHASE2
First recorded
Sep 2009
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Swiss Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .